Format

Send to

Choose Destination
Braz J Med Biol Res. 2016 Oct 24;49(11):e5644. doi: 10.1590/1414-431X20165644.

Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies.

Author information

1
Centro de Inovação e Ensaios Pré-clínicos, Florianópolis, SC, Brasil.

Abstract

This review presents a historical overview of drug discovery and the non-clinical stages of the drug development process, from initial target identification and validation, through in silico assays and high throughput screening (HTS), identification of leader molecules and their optimization, the selection of a candidate substance for clinical development, and the use of animal models during the early studies of proof-of-concept (or principle). This report also discusses the relevance of validated and predictive animal models selection, as well as the correct use of animal tests concerning the experimental design, execution and interpretation, which affect the reproducibility, quality and reliability of non-clinical studies necessary to translate to and support clinical studies. Collectively, improving these aspects will certainly contribute to the robustness of both scientific publications and the translation of new substances to clinical development.

PMID:
27783811
PMCID:
PMC5089235
DOI:
10.1590/1414-431X20165644
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online Icon for PubMed Central
Loading ...
Support Center